Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Raymond James Downgrades Teva Pharmaceutical Indus to Market Perform

Raymond James analyst Elliot Wilbur downgrades Teva Pharmaceutical Indus (NYSE:TEVA) from Outperform to Market Perform.

byBenzinga Newsdesk

October 28, 2021

1 minute read

Raymond James analyst Elliot Wilbur downgrades Teva Pharmaceutical Indus (NYSE:TEVA) from Outperform to Market Perform.

News

Mereo BioPharma Received Notification Of Nasdaq Minimum Bid Price Deficiency

By Benzinga Newsdesk

Today, 9:13 PM

Mereo BioPharma Group plc (NASDAQ:MREO), ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that on May 23, 2022, it received

MREO

Here’s How Much $1000 Invested In EPAM Sys 10 Years Ago Would Be Worth Today

By Benzinga Insights

Today, 9:13 PM

EPAM Sys (NYSE:EPAM) has outperformed the market over the past 10 years by 16.2% on an annualized basis producing an average annual return of 28.8%. Currently, EPAM Sys has a market capitalization of $15.58 billion.

EPAM